CoChat

A novel approach to inhibit bone resorption: exosite inhibitors against cathepsin K

Open access
Panwar, Preety, Søe, Kent, Guido, Rafael VC, Bueno, Renata V C, Delaisse, Jean‐Marie, Brömme, Dieter · 2016 · British Journal of Pharmacology
Cited by 71

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Background and Purpose: Cathepsin K (CatK) is a major drug target for the treatment of osteoporosis. Potent active site‐directed inhibitors have been developed and showed variable success in clinical trials. These inhibitors block the entire activity of CatK and thus may interfere with other pathways. The present study investigates the antiresorptive effect of an exosite inhibitor that selectively inhibits only the therapeutically relevant collagenase activity of CatK. Experimental Approach: Human osteoclasts and fibroblasts were used to analyse the effect of the exosite inhibitor, ortho‐dihydrotanshinone (DHT1), and the active site inhibitor, odanacatib (ODN), on bone resorption and TGF‐ß1 degradation. Cell cultures, Western blot, light and scanning electron microscopy as well as energy dispersive X‐ray spectroscopy, molecular modelling and enzymatic assays were used to evaluate the inhibitors. Key Results: DHT1 selectively inhibited the collagenase activity of CatK, without affecting the viability of osteoclasts. Both inhibitors abolished the formation of resorption trenches, with DHT1 having a slightly higher IC 50 value than ODN. Maximal reductions of other resorption parameters by DHT1 and ODN were comparable, respectively 41% and 33% for total resorption surface, 46% and 48% for resorption depths, and 83% and 61% for C‐terminal telopetide fragment (CTX) release. DHT1 did not affect the turnover of fibrosis‐associated TGF‐ß1 in fibroblasts, whereas 500 nM ODN was inhibitory. Conclusions and Implications: Our study shows that an exosite inhibitor of CatK can specifically block bone resorption without interfering with other pathways.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bph.13383

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy

    Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., Repasky, M. P., Knoll, E. H., Shelley, M., Perry, J. K., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0306430 · Cited by 10,057 · cited 2×

    “Molecular docking was performed on the CatK structure (Protein Data Base ID#: 4DMX) (Dossetter et al., 2012) using the GLIDE programme (Friesner et al., 2004) (version 6.2, Schrodinger, LLC, New York, NY, USA, 2014).”
    MethodInfluential
  • TGF-β signaling and the fibrotic response

    Leask, A., & Abraham, D. J. (2004) · The FASEB Journal · doi:10.1096/fj.03-1273rev · Cited by 2,319 · cited 1×

    “Deregulation of TGF-ß1 expression and metabolism has been associated with fibrotic diseases including morphea (Leask and Abraham, 2004), which was the terminating factor of the balicatib clinical trial (Runger et al., 2012).”
    Background
  • Disorders of Bone Remodeling

    Feng, X., & McDonald, J. M. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130203 · Cited by 1,272 · cited 1×

    “Docking was performed using XP (Extra Precision mode) docking protocol (Friesner et al., 2006), and visual inspection was employed to select the representative conformation for the exosite inhibitor.”
    Method

Show all 3 references

Cited by

Metadata

Authors
Panwar, P., Søe, K., Guido, R. V., Bueno, R. V. C., Delaisse, J., & Brömme, D.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2015-12-16
Volume
173
Issue
2
Pages
396-410
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W2140242036
Cited by
71
References
3
FWCI
2.44
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.